Abcam, ab251179, Anti-PHKG1 antibody [EPR14812] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal PHKG1 antibody. Carrier free. Suitable for ICC/IF, WB, IHC-P and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14812,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, ICC/IF, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251179 is the carrier-free version of
ab194112
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4 Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PHKG1 is also known as phosphorylase kinase gamma 1. PHKG1 is an enzyme that plays a role in phosphorylase kinase activity. This enzyme has a molecular mass of approximately 45 kDa. Researchers found PHKG1 expressed mainly in skeletal muscle tissue where it participates in glycogen metabolism. The enzyme contains catalytic subunits that function in phosphorylating serine and threonine residues essential for glycogen breakdown.
Biological function summary
PHKG1 acts as a critical component of the larger phosphorylase kinase complex. This complex promotes glycogenolysis the process of converting glycogen to glucose-1-phosphate facilitating energy release in cells. Within tissues PHKG1 interacts with other subunits of phosphorylase kinase playing a regulatory role. Effective activation of phosphorylase b to active phosphorylase a form relies on efficient PHKG1 function.
Pathways
PHKG1 is essential in the glycogenolysis pathway. It interacts with AMP-activated protein kinase (AMPK). Besides PHKG1 associates with cAMP-dependent protein kinase (PKA) as both enzymes participate in regulating energy homeostasis. These interactions highlight the enzyme’s function in maintaining metabolic balance under stress conditions.
PHKG1 associates with McArdle's disease a glycogen storage disorder characterized by muscle weakness and fatigue. Aberrant PHKG1 activity can disrupt glycogen breakdown aggravating symptoms of the condition. Moreover metabolic syndrome a cluster of metabolic disorders connects to PHKG1 through its role in regulating glucose metabolism and shares common pathways with AMPK relating PHKG1 to potential targets for therapy in metabolic disorders.